The paradigm of drug resistance in cancer: an epigenetic perspective

Drug resistance and Cancer stem cells

(2021) Yuan Li et al.   Cell Communication and Signaling

A dose escalation study of RO6870810/TEN-10 in patients with acute myeloid leukemia and myelodysplastic syndrome

(2021) Gail J. Roboz et al.   LEUKEMIA & LYMPHOMA

FK228 sensitizes radioresistant small cell lung cancer cells to radiation

(2021) Hong Li et al.   Clinical Epigenetics

Achieving clinical success with BET inhibitors as anti-cancer agents

(2021) Tatiana Shorstova et al.   BRITISH JOURNAL OF CANCER

Chemotherapy-elicited exosomal miR-378a-3p and miR-378d promote breast cancer stemness and chemoresistance via the activation of EZH2/STAT3 signaling

(2021) Qianxi Yang et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

A phase 1b dose-escalation/expansion study of BET inhibitor RO6870810 in patients with advanced multiple myeloma

(2021) Karthik Ramasamy et al.   Blood Cancer Journal

Current understanding of epigenetics mechanism as a novel target in reducing cancer stem cells resistance

(2021) Saeedeh Keyvani-Ghamsari et al.   Clinical Epigenetics

Non-canonical H3K79me2-dependent pathways promote the survival of MLL-rearranged leukemia

(2021) William F Richter et al.   eLife

EZH2i EPZ-6438 and HDACi vorinostat synergize with ONC201/TIC10 to activate integrated stress response, DR5, reduce H3K27 methylation, ClpX and promote apoptosis of multiple tumor types including DIPG

(2021) Yiqun Zhang et al.   NEOPLASIA

Epigenetic Deregulation of Apoptosis in Cancers

(2021) Ezgi Ozyerli-Goknar et al.   Cancers

Tazemetostat: a treatment option for relapsed/refractory follicular lymphoma

(2021) Patrizia Mondello et al.   EXPERT OPINION ON PHARMACOTHERAPY

EZH2 presents a therapeutic target for neuroendocrine tumors of the small intestine

(2021) Elham Barazeghi et al.   Scientific Reports

Combined tazemetostat and MAPKi enhances differentiation of papillary thyroid cancer cells harbouring BRAF V600E by synergistically decreasing global trimethylation of H3K27

(2020) Hao Fu et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Elevated HDAC activity and altered histone phospho-acetylation confer acquired radio-resistant phenotype to breast cancer cells

(2020) Asmita Sharda et al.   Clinical Epigenetics

Repositioning Aspirin to Treat Lung and Breast Cancers and Overcome Acquired Resistance to Targeted Therapy

(2020) Ling Li et al.   Frontiers in Oncology

The Promise for Histone Methyltransferase Inhibitors for Epigenetic Therapy in Clinical Oncology: A Narrative Review

(2020) Hope S. Rugo et al.   ADVANCES IN THERAPY

Loci specific epigenetic drug sensitivity

(2020) Thanutra Zhang et al.   NUCLEIC ACIDS RESEARCH

Tumor microenvironment remodeling enables bypass of oncogenic KRAS dependency in pancreatic cancer

(2020) Pingping Hou et al.   Cancer Discovery

Cancer Stem Cells as a Potential Target to Overcome Multidrug Resistance

(2020) Yena Cho et al.   Frontiers in Oncology

Epigenetic regulation of differentially expressed Drug-metabolizing enzymes in cancer

(2020) Jiaqi Wang et al.   DRUG METABOLISM AND DISPOSITION

The Contribution of Epigenetics to Cancer Immunotherapy

(2020) Lorea Villanueva et al.   TRENDS IN IMMUNOLOGY

The Interplay among miRNAs, Major Cytokines, and Cancer-Related Inflammation

(2020) Chiranjib Chakraborty et al.   Molecular Therapy-Nucleic Acids

The Roles of Cancer Stem Cells and Therapy Resistance in Colorectal Carcinoma

(2020) Plabon Kumar Das et al.   Cells

Synergistic antitumor interaction of valproic acid and simvastatin sensitizes prostate cancer to docetaxel by targeting CSCs compartment via YAP inhibition

(2020) Federica Iannelli et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

SMAR1 repression by pluripotency factors and consequent chemoresistance in breast cancer stem-like cells is reversed by aspirin

(2020) Apoorva Bhattacharya et al.   Science Signaling

BET degrader inhibits tumor progression and stem-like cell growth via Wnt/β-catenin signaling repression in glioma cells

(2020) Tao Tian et al.   Cell Death & Disease

Counteracting Chemoresistance with Metformin in Breast Cancers: Targeting Cancer Stem Cells

(2020) Samson Mathews Samuel et al.   Cancers

Aberrant DNA Methylation of ABC Transporters in Cancer

(2020) Katja Zappe et al.   Cells

Valproic Acid Synergizes With Cisplatin and Cetuximab in vitro and in vivo in Head and Neck Cancer by Targeting the Mechanisms of Resistance

(2020) Federica Iannelli et al.   Frontiers in Cell and Developmental Biology

Inhibition of EZH2 enhances the therapeutic effect of 5-FU via PUMA upregulation in colorectal cancer

(2020) Xiao Tan et al.   Cell Death & Disease

Suppression of poised oncogenes by ZMYND8 promotes chemo-sensitization

(2020) Shravanti Mukherjee et al.   Cell Death & Disease

Low doses of decitabine improve the chemotherapy efficacy against basal-like bladder cancer by targeting cancer stem cells

(2019) Mingqing Wu et al.   ONCOGENE

LSD1 Inhibition Attenuates Tumor Growth by Disrupting PLK1 Mitotic Pathway

(2019) Priya S. Dalvi et al.   MOLECULAR CANCER RESEARCH

Targeting Tumor Microenvironment for Cancer Therapy

(2019) Catarina Roma-Rodrigues et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Interaction of tumor-associated macrophages and cancer chemotherapy

(2019) Irina Larionova et al.   OncoImmunology

An Evolutionarily Conserved Function of Polycomb Silences the MHC Class I Antigen Presentation Pathway and Enables Immune Evasion in Cancer

(2019) Marian L. Burr et al.   CANCER CELL

Paradoxical effects of chemotherapy on tumor relapse and metastasis promotion

(2019) Crescenzo D’Alterio et al.   SEMINARS IN CANCER BIOLOGY

Correction: Synergistic interactions between PLK1 and HDAC inhibitors in non-Hodgkin’s lymphoma cells occur in vitro and in vivo and proceed through multiple mechanisms

(2019) Tri Nguyen et al.   Oncotarget

The Tumor Microenvironment in Colorectal Cancer Therapy

(2019) Leire Pedrosa et al.   Cancers

Aspirin suppresses chemoresistance and enhances antitumor activity of 5-Fu in 5-Fu-resistant colorectal cancer by abolishing 5-Fu-induced NF-κB activation

(2019) Jinbo Fu et al.   Scientific Reports

Inhibition of Histone Demethylases LSD1 and UTX Regulates ERα Signaling in Breast Cancer

(2019) Rosaria Benedetti et al.   Cancers

The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia

(2018) Eytan M. Stein et al.   BLOOD

Pan-HDAC inhibition by panobinostat mediates chemosensitization to carboplatin in non-small cell lung cancer via attenuation of EGFR signaling

(2018) Lingzhi Wang et al.   CANCER LETTERS

Reactivation of endogenous retroviral elements via treatment with DNMT- and HDAC-inhibitors

(2018) Michael Daskalakis et al.   CELL CYCLE

Apoptosis: A Target for Anticancer Therapy

(2018) et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

H2A.Z regulates tumorigenesis, metastasis and sensitivity to cisplatin in intrahepatic cholangiocarcinoma

(2018) Beng Yang et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

Hyper-acetylation contributes to the sensitivity of chemo-resistant prostate cancer cells to histone deacetylase inhibitor Trichostatin A

(2018) Qingqing Xu et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Downregulation of miR‑135a predicts poor prognosis in acute myeloid leukemia and regulates leukemia progression via modulating HOXA10 expression

(2018) Hongwei Xu et al.   Molecular Medicine Reports

CASC2/miR-24/miR-221 modulates the TRAIL resistance of hepatocellular carcinoma cell through caspase-8/caspase-3

(2018) Xiaoxin Jin et al.   Cell Death & Disease

Curcumin inhibits the growth of liver cancer stem cells through the phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin signaling pathway

(2018) Ji Wang et al.   Experimental and Therapeutic Medicine

Mutant p53 cancers reprogram macrophages to tumor supporting macrophages via exosomal miR-1246

(2018) Tomer Cooks et al.   Nature Communications

Depletion of HDAC1, 7 and 8 by Histone Deacetylase Inhibition Confers Elimination of Pancreatic Cancer Stem Cells in Combination with Gemcitabine

(2018) Mao-Hua Cai et al.   Scientific Reports

The BET inhibitor I-BET762 inhibits pancreatic ductal adenocarcinoma cell proliferation and enhances the therapeutic effect of gemcitabine

(2018) Fang Xie et al.   Scientific Reports

LSD1 activation promotes inducible EMT programs and modulates the tumour microenvironment in breast cancer

(2018) T. Boulding et al.   Scientific Reports

Dual role of HDAC10 in lysosomal exocytosis and DNA repair promotes neuroblastoma chemoresistance

(2018) Johannes Ridinger et al.   Scientific Reports

Targeting EZH2 Reprograms Intratumoral Regulatory T Cells to Enhance Cancer Immunity

(2018) David Wang et al.   Cell Reports

Cancer Stem Cells (CSCs) in Drug Resistance and their Therapeutic Implications in Cancer Treatment

(2018) Lan Thi Hanh Phi et al.   Stem Cells International

DNA Damage, Repair, and Cancer Metabolism

(2018) Marc-Olivier Turgeon et al.   Frontiers in Oncology

MicroRNA-135a-3p is downregulated and serves as a tumour suppressor in ovarian cancer by targeting CCR2

(2018) Shufeng Duan et al.   BIOMEDICINE & PHARMACOTHERAPY

Dual inhibition of DNA and histone methyltransferases increases viral mimicry in ovarian cancer cells

(2018) Minmin Liu et al.   CANCER RESEARCH

Valproic acid as an adjunctive therapeutic agent for the treatment of breast cancer

(2018) Hayley Heers et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

KDM4B-regulated unfolded protein response as a therapeutic vulnerability in PTEN-deficient breast cancer

(2018) Wenyu Wang et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Potent Activity of the Bromodomain Inhibitor OTX015 in Multiple Myeloma

(2018) Jixiang Shi et al.   MOLECULAR PHARMACEUTICS

The Jumonji-domain histone demethylase inhibitor JIB-04 deregulates oncogenic programs and increases DNA damage in Ewing Sarcoma, resulting in impaired cell proliferation and survival, and reduced tumor growth

(2018) Janet K. Parrish et al.   Oncotarget

Cancer stem cells (CSCs) in cancer progression and therapy

(2018) Masoud Najafi et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Enhancing chemosensitivity of breast cancer stem cells by down regulating SOX2 and ABCG2 using Wedelolactone-encapsulated nanoparticles

(2018) Sreemanti Das et al.   MOLECULAR CANCER THERAPEUTICS

Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia

(2018) Daniel A. Pollyea et al.   NATURE MEDICINE

NOXA genetic amplification or pharmacologic induction primes lymphoma cells to BCL2 inhibitor-induced cell death

(2018) Yuxuan Liu et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Therapy resistance mediated by cancer stem cells

(2018) Teresa Bernadette Steinbichler et al.   SEMINARS IN CANCER BIOLOGY

Hepatoma-intrinsic CCRK inhibition diminishes myeloid-derived suppressor cell immunosuppression and enhances immune-checkpoint blockade efficacy

(2017) Jingying Zhou et al.   GUT

The DNA Methylcytosine Dioxygenase Tet2 Sustains Immunosuppressive Function of Tumor-Infiltrating Myeloid Cells to Promote Melanoma Progression

(2017) Wen Pan et al.   IMMUNITY

Drug Resistance Driven by Cancer Stem Cells and Their Niche

(2017) Marta Prieto-Vila et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Regulation of DNA Repair Mechanisms: How the Chromatin Environment Regulates the DNA Damage Response

(2017) Jens Stadler et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Chromatin Dynamics in Genome Stability: Roles in Suppressing Endogenous DNA Damage and Facilitating DNA Repair

(2017) Nidhi Nair et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Procaine is a specific DNA methylation inhibitor with anti-tumor effect for human gastric cancer

(2017) Yong-Chao Li et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

Optimization of Orally Bioavailable Enhancer of Zeste Homolog 2 (EZH2) Inhibitors Using Ligand and Property-Based Design Strategies: Identification of Development Candidate (R)-5,8-Dichloro-7-(methoxy(oxetan-3-yl)methyl)-2-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-3,4-dihydroisoquinolin-1(2H)-one (PF-06821497)

(2017) Pei-Pei Kung et al.   JOURNAL OF MEDICINAL CHEMISTRY

Epigenetic drug combination overcomes osteoblast-induced chemoprotection in pediatric acute lymphoid leukemia

(2017) Anthony Quagliano et al.   LEUKEMIA RESEARCH

Reversal of platinum drug resistance by the histone deacetylase inhibitor belinostat

(2017) Kenneth Kin-Wah To et al.   LUNG CANCER

Epigenetics in cancer stem cells

(2017) Tan Boon Toh et al.   Molecular Cancer

Dual inhibition of DNMTs and EZH2 can overcome both intrinsic and acquired resistance of myeloma cells to IMiDs in a cereblon-independent manner

(2017) Konstantinos Dimopoulos et al.   Molecular Oncology

EMT, CSCs, and drug resistance: the mechanistic link and clinical implications

(2017) Tsukasa Shibue et al.   Nature Reviews Clinical Oncology

Phase I/II trial of vorinostat combined with temozolomide and radiation therapy for newly diagnosed glioblastoma: results of Alliance N0874/ABTC 02

(2017) Evanthia Galanis et al.   NEURO-ONCOLOGY

MUC1 induces acquired chemoresistance by upregulating ABCB1 in EGFR-dependent manner

(2017) Wei Jin et al.   Cell Death & Disease

The EZH2 inhibitor GSK343 suppresses cancer stem-like phenotypes and reverses mesenchymal transition in glioma cells

(2017) Tianfu Yu et al.   Oncotarget

Apoptosis as anticancer mechanism: function and dysfunction of its modulators and targeted therapeutic strategies

(2016) Giuseppa Pistritto et al.   Aging-US

Epigenetic Therapeutics: A New Weapon in the War Against Cancer

(2016) Nita Ahuja et al.   Annual Review of Medicine

The NAE inhibitor pevonedistat interacts with the HDAC inhibitor belinostat to target AML cells by disrupting the DDR

(2016) L. Zhou et al.   BLOOD

Cancer treatment and survivorship statistics, 2016

(2016) Kimberly D. Miller et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Aspirin Suppresses the Acquisition of Chemoresistance in Breast Cancer by Disrupting an NFκB–IL6 Signaling Axis Responsible for the Generation of Cancer Stem Cells

(2016) Shilpi Saha et al.   CANCER RESEARCH

An Epigenetic Reprogramming Strategy to Resensitize Radioresistant Prostate Cancer Cells

(2016) C. Peitzsch et al.   CANCER RESEARCH

The cancer stem-cell signaling network and resistance to therapy

(2016) A. Carnero et al.   CANCER TREATMENT REVIEWS

MiR-153 as a Tumor Suppressor in Glioblastoma Multiforme is Downregulated by DNA Methylation

(2016) Asghar Ghasemi et al.   Clinical Laboratory

Bromodomain inhibitors and cancer therapy: From structures to applications

(2016) Montserrat Pérez-Salvia et al.   Epigenetics

Targeting epigenetic regulators for cancer therapy: modulation of bromodomain proteins, methyltransferases, demethylases, and microRNAs

(2016) Kathy A. Gelato et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Panobinostat sensitizes cyclin E high, homologous recombination-proficient ovarian cancer to olaparib

(2016) Andrew J. Wilson et al.   GYNECOLOGIC ONCOLOGY

Epigenetic regulators and their impact on therapy in acute myeloid leukemia

(2016) F. Pastore et al.   HAEMATOLOGICA

Promising in vivo efficacy of the BET bromodomain inhibitor OTX015/MK-8628 in malignant pleural mesothelioma xenografts

(2016) Ramiro Vázquez et al.   INTERNATIONAL JOURNAL OF CANCER

Identification of (R)-N-((4-Methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide (CPI-1205), a Potent and Selective Inhibitor of Histone Methyltransferase EZH2, Suitable for Phase I Clinical Trials for B-Cell Lymphomas

(2016) Rishi G. Vaswani et al.   JOURNAL OF MEDICINAL CHEMISTRY

Dynamic changes in the clonal structure of MDS and AML in response to epigenetic therapy

(2016) G L Uy et al.   LEUKEMIA

ATM Mutations in Cancer: Therapeutic Implications

(2016) M. Choi et al.   MOLECULAR CANCER THERAPEUTICS

Targeting Epithelial–Mesenchymal Transition (EMT) to Overcome Drug Resistance in Cancer

(2016) Bowen Du et al.   MOLECULES

Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer

(2016) Shaokun Shu et al.   NATURE

Inhibition of BET bromodomain-dependent XIAP and FLIP expression sensitizes KRAS-mutated NSCLC to pro-apoptotic agents

(2016) Olaf Klingbeil et al.   Cell Death & Disease

Protein arginine methylation/demethylation and cancer

(2016) Coralie Poulard et al.   Oncotarget

Epigenetic regulators and their impact on therapy in acute myeloid leukemia

(2016) F. Pastore et al.   HAEMATOLOGICA

Lysine-Specific Demethylase 1 (LSD1) Inhibitor S2101 Induces Autophagy via the AKT/mTOR Pathway in SKOV3 Ovarian Cancer Cells

(2016) Shujun Feng et al.   MEDICAL SCIENCE MONITOR

Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study

(2016) Céline Berthon et al.   Lancet Haematology

Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study

(2016) Sandy Amorim et al.   Lancet Haematology

Preclinical Evidence of Anti-Tumor Activity Induced by EZH2 Inhibition in Human Models of Synovial Sarcoma

(2016) Satoshi Kawano et al.   PLoS One

Enhancing SHP-1 expression with 5-azacytidine may inhibit STAT3 activation and confer sensitivity in lestaurtinib (CEP-701)-resistant FLT3-ITD positive acute myeloid leukemia

(2015) Hamid Ali Nagi Al-Jamal et al.   BMC CANCER

The pan-HDAC inhibitor panobinostat acts as a sensitizer for erlotinib activity in EGFR-mutated and -wildtype non-small cell lung cancer cells

(2015) Gabriele Greve et al.   BMC CANCER

Synergistic anti-leukemic interactions between panobinostat and MK-1775 in acute myeloid leukemia ex vivo

(2015) Wenxiu Qi et al.   CANCER BIOLOGY & THERAPY

Targeting colorectal cancer stem cells using curcumin and curcumin analogues: insights into the mechanism of the therapeutic efficacy

(2015) Thamil Selvee Ramasamy et al.   Cancer Cell International

Survival of skin cancer stem cells requires the Ezh2 polycomb group protein

(2015) Gautam Adhikary et al.   CARCINOGENESIS

DNA-Demethylating Agents Target Colorectal Cancer Cells by Inducing Viral Mimicry by Endogenous Transcripts

(2015) David Roulois et al.   CELL

TGF-β Promotes Heterogeneity and Drug Resistance in Squamous Cell Carcinoma

(2015) Naoki Oshimori et al.   CELL

The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs

(2015) M. Boi et al.   CLINICAL CANCER RESEARCH

SMO Gene Amplification and Activation of the Hedgehog Pathway as Novel Mechanisms of Resistance to Anti-Epidermal Growth Factor Receptor Drugs in Human Lung Cancer

(2015) C. M. Della Corte et al.   CLINICAL CANCER RESEARCH

Targeting MYCN-Driven Transcription By BET-Bromodomain Inhibition

(2015) A. Henssen et al.   CLINICAL CANCER RESEARCH

Molecular Connections between Cancer Cell Metabolism and the Tumor Microenvironment

(2015) Calvin Justus et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

The epigenetic agents suberoylanilide hydroxamic acid and 5-AZA-2′ deoxycytidine decrease cell proliferation, induce cell death and delay the growth of MiaPaCa2 pancreatic cancer cells in vivo

(2015) JOHANA M. SUSANTO et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

Chemoresistance to doxorubicin induces epithelial-mesenchymal transition via upregulation of transforming growth factor β signaling in HCT116 colon cancer cells

(2015) JINPENG LI et al.   Molecular Medicine Reports

Decitabine Nanoconjugate Sensitizes Human Glioblastoma Cells to Temozolomide

(2015) Yi Cui et al.   MOLECULAR PHARMACEUTICS

Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer

(2015) Xiaofeng Zheng et al.   NATURE

Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy

(2015) Dongjun Peng et al.   NATURE

A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL models

(2015) Elayne Chan-Penebre et al.   Nature Chemical Biology

MiRNA-621 sensitizes breast cancer to chemotherapy by suppressing FBXO11 and enhancing p53 activity

(2015) J Xue et al.   ONCOGENE

Valproic acid suppresses the self-renewal and proliferation of head and neck cancer stem cells

(2015) SANG HYUK LEE et al.   ONCOLOGY REPORTS

EZH2 is crucial for both differentiation of regulatory T cells and T effector cell expansion

(2015) Xiang-Ping Yang et al.   Scientific Reports

Overcoming Multidrug Resistance in Cancer Stem Cells

(2015) Karobi Moitra   Biomed Research International

Analysis of DNA methylation landscape reveals the roles of DNA methylation in the regulation of drug metabolizing enzymes

(2015) Wataru Habano et al.   Clinical Epigenetics

Epigenetic regulation of drug metabolism and transport

(2015) Lai Peng et al.   Acta Pharmaceutica Sinica B

Upregulation of microRNA-492 induced by epigenetic drug treatment inhibits the malignant phenotype of clear cell renal cell carcinoma in vitro

(2015) AIBING WU et al.   Molecular Medicine Reports

miR-34 and p53: New Insights into a Complex Functional Relationship

(2015) Francisco Navarro et al.   PLoS One

The role of DNA damage and repair in decitabine-mediated apoptosis in multiple myeloma

(2015) Ken Maes et al.   Oncotarget

HDAC 1/4-mediated silencing of microRNA-200b promotes chemoresistance in human lung adenocarcinoma cells

(2015) Dong-Qin Chen et al.   Oncotarget

Chemotherapeutic Drug-Induced ABCG2 Promoter Demethylation as a Novel Mechanism of Acquired Multidrug Resistance

(2015) Eran E. Bram et al.   NEOPLASIA

A class I histone deacetylase inhibitor, entinostat, enhances lapatinib efficacy in HER2-overexpressing breast cancer cells through FOXO3-mediated Bim1 expression

(2014) Jangsoon Lee et al.   BREAST CANCER RESEARCH AND TREATMENT

Phase I study of anti-VEGF monoclonal antibody bevacizumab and histone deacetylase inhibitor valproic acid in patients with advanced cancers

(2014) Jennifer J. Wheler et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Abstract B31: Expression of Wnt3 activates Wnt/β-catenin pathway and promotes EMT-like phenotype in trastuzumab resistant HER2-overexpressing breast cancer cells.

(2014) Yanyuan Wu et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

Afatinib Enhances the Efficacy of Conventional Chemotherapeutic Agents by Eradicating Cancer Stem-like Cells

(2014) X.-k. Wang et al.   CANCER RESEARCH

The Cancer Stem Cell Marker Aldehyde Dehydrogenase Is Required to Maintain a Drug-Tolerant Tumor Cell Subpopulation

(2014) D. Raha et al.   CANCER RESEARCH

The paradigm of mutant p53-expressing cancer stem cells and drug resistance

(2014) Yoav Shetzer et al.   CARCINOGENESIS

Evolution of the Cancer Stem Cell Model

(2014) Antonija Kreso et al.   Cell Stem Cell

A Phase I/II Trial of Belinostat in Combination with Cisplatin, Doxorubicin, and Cyclophosphamide in Thymic Epithelial Tumors: A Clinical and Translational Study

(2014) A. Thomas et al.   CLINICAL CANCER RESEARCH

Epigenetic Regulation of EMT: The Snail Story

(2014) Yiwei Lin et al.   CURRENT PHARMACEUTICAL DESIGN

5-Azacytidine enhances efficacy of multiple chemotherapy drugs in AML and lung cancer with modulation of CpG methylation

(2014) MATHIAS FÜLLER et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

New and emerging HDAC inhibitors for cancer treatment

(2014) Alison C. West et al.   JOURNAL OF CLINICAL INVESTIGATION

Histone Deacetylase Inhibitor Sensitizes Apoptosis-Resistant Melanomas to Cytotoxic Human T Lymphocytes through Regulation of TRAIL/DR5 Pathway

(2014) A. R. Jazirehi et al.   JOURNAL OF IMMUNOLOGY

Selective Inhibition of EZH2 by EPZ-6438 Leads to Potent Antitumor Activity in EZH2-Mutant Non-Hodgkin Lymphoma

(2014) S. K. Knutson et al.   MOLECULAR CANCER THERAPEUTICS

Cancer Epigenetics: Tumor Heterogeneity, Plasticity of Stem-like States, and Drug Resistance

(2014) Hariharan Easwaran et al.   MOLECULAR CELL

Blocking PGE2-induced tumour repopulation abrogates bladder cancer chemoresistance

(2014) Antonina V. Kurtova et al.   NATURE

Histone deacetylase inhibitor (HDACI) mechanisms of action: Emerging insights

(2014) Prithviraj Bose et al.   PHARMACOLOGY & THERAPEUTICS

Correction: CDKN1C (p57KIP2) Is a Direct Target of EZH2 and Suppressed by Multiple Epigenetic Mechanisms in Breast Cancer Cells

(2014) Xiaojing Yang et al.   PLoS One

Treatment of Nasopharyngeal Carcinoma Cells with the Histone-Deacetylase Inhibitor Abexinostat: Cooperative Effects with Cis-platin and Radiotherapy on Patient-Derived Xenografts

(2014) Mélanie Gressette et al.   PLoS One

Dual epigenetic targeting with panobinostat and azacitidine in acute myeloid leukemia and high-risk myelodysplastic syndrome

(2014) P Tan et al.   Blood Cancer Journal

Drug Resistance in Cancer: An Overview

(2014) Genevieve Housman et al.   Cancers

Romidepsin for the treatment of T-cell lymphomas

(2013) A. L. McGraw   AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY

Synergistic induction of cancer cell death and reduction of clonogenic resistance by cisplatin and FK228

(2013) Shambhunath Choudhary et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Potent inhibition of DOT1L as treatment of MLL-fusion leukemia

(2013) S. R. Daigle et al.   BLOOD

Potent antimyeloma activity of the novel bromodomain inhibitors I-BET151 and I-BET762

(2013) A. Chaidos et al.   BLOOD

Melatonin-induced methylation of the ABCG2/BCRP promoter as a novel mechanism to overcome multidrug resistance in brain tumour stem cells

(2013) V Martín et al.   BRITISH JOURNAL OF CANCER

Activity of histone deacetylase inhibitors and an Aurora kinase inhibitor in BCR-ABL-expressing leukemia cells: Combination of HDAC and Aurora inhibitors in BCR-ABL-expressing cells

(2013) Seiichi Okabe et al.   Cancer Cell International

Histone variants: emerging players in cancer biology

(2013) Chiara Vardabasso et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

The Histone Deacetylase Inhibitor Abexinostat Induces Cancer Stem Cells Differentiation in Breast Cancer with Low Xist Expression

(2013) M. A. Salvador et al.   CLINICAL CANCER RESEARCH

BET Bromodomain Inhibition of MYC-Amplified Medulloblastoma

(2013) P. Bandopadhayay et al.   CLINICAL CANCER RESEARCH

Overexpression of CARM1 in breast cancer is correlated with poorly characterized clinicopathologic parameters and molecular subtypes

(2013) Hongxia Cheng et al.   Diagnostic Pathology

The ZEB1 pathway links glioblastoma initiation, invasion and chemoresistance

(2013) Florian A. Siebzehnrubl et al.   EMBO Molecular Medicine

Zebularine partially reverses GST methylation in prostate cancer cells and restores sensitivity to the DNA minor groove binder brostallicin

(2013) Maria Antonietta Sabatino et al.   Epigenetics

TGF-β inhibition enhances chemotherapy action against triple-negative breast cancer

(2013) Neil E. Bhola et al.   JOURNAL OF CLINICAL INVESTIGATION

Systematic Screen Identifies miRNAs That Target RAD51 and RAD51D to Enhance Chemosensitivity

(2013) J.-W. Huang et al.   MOLECULAR CANCER RESEARCH

Mutational landscape and significance across 12 major cancer types

(2013) Cyriac Kandoth et al.   NATURE

Mutations in regulators of the epigenome and their connections to global chromatin patterns in cancer

(2013) Christoph Plass et al.   NATURE REVIEWS GENETICS

Effects of the monoamine oxidase inhibitors pargyline and tranylcypromine on cellular proliferation in human prostate cancer cells

(2013) HYUNG TAE LEE et al.   ONCOLOGY REPORTS

BET Inhibition Silences Expression of MYCN and BCL2 and Induces Cytotoxicity in Neuroblastoma Tumor Models

(2013) Anastasia Wyce et al.   PLoS One

Chromatin Compaction Protects Genomic DNA from Radiation Damage

(2013) Hideaki Takata et al.   PLoS One

Evading apoptosis in cancer

(2013) Kaleigh Fernald et al.   TRENDS IN CELL BIOLOGY

Epigenetic Modulating Agents as a New Therapeutic Approach in Multiple Myeloma

(2013) Ken Maes et al.   Cancers

DNA methylation inhibitors in cancer: Recent and future approaches

(2012) Christina Gros et al.   BIOCHIMIE

Epigenetic silencing of microRNA-193a contributes to leukemogenesis in t(8;21) acute myeloid leukemia by activating the PTEN/PI3K signal pathway

(2012) Y. Li et al.   BLOOD

Suppression of Acquired Docetaxel Resistance in Prostate Cancer through Depletion of Notch- and Hedgehog-Dependent Tumor-Initiating Cells

(2012) Josep Domingo-Domenech et al.   CANCER CELL

Phase I study of 5-aza-2′-deoxycytidine in combination with valproic acid in non-small-cell lung cancer

(2012) B. F. Chu et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

ALDH-positive lung cancer stem cells confer resistance to epidermal growth factor receptor tyrosine kinase inhibitors

(2012) Cheng-Po Huang et al.   CANCER LETTERS

Cisplatin Sensitivity Mediated by WEE1 and CHK1 Is Mediated by miR-155 and the miR-15 Family

(2012) L. M. Pouliot et al.   CANCER RESEARCH

Hypoxia-Induced MicroRNA-20a Expression Increases ERK Phosphorylation and Angiogenic Gene Expression in Endometriotic Stromal Cells

(2012) Shih-Chieh Lin et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Therapeutic strategies in epithelial ovarian cancer

(2012) Ayako Kim et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Reexpression of Tumor Suppressor, sFRP1, Leads to Antitumor Synergy of Combined HDAC and Methyltransferase Inhibitors in Chemoresistant Cancers

(2012) S. J. Cooper et al.   MOLECULAR CANCER THERAPEUTICS

Development of Gene Expression-Based Score to Predict Sensitivity of Multiple Myeloma Cells to DNA Methylation Inhibitors

(2012) J. Moreaux et al.   MOLECULAR CANCER THERAPEUTICS

Chromatin organization is a major influence on regional mutation rates in human cancer cells

(2012) Benjamin Schuster-Böckler et al.   NATURE

EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations

(2012) Michael T. McCabe et al.   NATURE

Class I Histone Deacetylase Inhibitor Entinostat Suppresses Regulatory T Cells and Enhances Immunotherapies in Renal and Prostate Cancer Models

(2012) Li Shen et al.   PLoS One

Reference miRNAs for miRNAome Analysis of Urothelial Carcinomas

(2012) Nadine Ratert et al.   PLoS One

miR-20a targets BNIP2 and contributes chemotherapeutic resistance in colorectal adenocarcinoma SW480 and SW620 cell lines

(2011) H. Chai et al.   ACTA BIOCHIMICA ET BIOPHYSICA SINICA

Heterochromatin and the DNA damage response: the need to relaxThis paper is one of a selection of papers in a Special Issue entitled 31st Annual International Asilomar Chromatin and Chromosomes Conference, and has undergone the Journal’s usual peer review process.

(2011) Kendra L. Cann et al.   Biochemistry and Cell Biology

Histone deacetylases mediate the silencing of miR-15a, miR-16, and miR-29b in chronic lymphocytic leukemia

(2011) D. Sampath et al.   BLOOD

Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma

(2011) R. L. Piekarz et al.   BLOOD

Human microRNA-27a* targets Prf1 and GzmB expression to regulate NK-cell cytotoxicity

(2011) T.-D. Kim et al.   BLOOD

Cooperation of the HDAC inhibitor vorinostat and radiation in metastatic neuroblastoma: Efficacy and underlying mechanisms

(2011) Sabine Mueller et al.   CANCER LETTERS

Intrinsic Anticancer Drug Resistance of Malignant Melanoma Cells Is Abrogated by IFN-  and Valproic Acid

(2011) W. P. Roos et al.   CANCER RESEARCH

Functional Activation of the Estrogen Receptor-  and Aromatase by the HDAC Inhibitor Entinostat Sensitizes ER-Negative Tumors to Letrozole

(2011) G. J. Sabnis et al.   CANCER RESEARCH

TLR signaling-mediated differential histone modification at IL-10 and IL-12 promoter region leads to functional impairments in tumor-associated macrophages

(2011) Sayantan Banerjee et al.   CARCINOGENESIS

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

Vorinostat, SAHA, represses telomerase activity via epigenetic regulation of telomerase reverse transcriptase in non-small cell lung cancer cells

(2011) Chien-Te Li et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

Activation of Notch-1 enhances epithelial-mesenchymal transition in gefitinib-acquired resistant lung cancer cells

(2011) Mian Xie et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast Cancer

(2011) Nicholas J. Robert et al.   JOURNAL OF CLINICAL ONCOLOGY

Hypoxia-microRNA-16 downregulation induces VEGF expression in anaplastic lymphoma kinase (ALK)-positive anaplastic large-cell lymphomas

(2011) E Dejean et al.   LEUKEMIA

Expression of selected gene for acquired drug resistance to EGFR-TKI in lung adenocarcinoma

(2011) Hidetaka Uramoto et al.   LUNG CANCER

RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia

(2011) Johannes Zuber et al.   NATURE

Treatment of multiple myeloma

(2011) S. Vincent Rajkumar   Nature Reviews Clinical Oncology

A Pilot Phase II Study of Valproic Acid for Treatment of Low-Grade Neuroendocrine Carcinoma

(2011) T. A. Mohammed et al.   ONCOLOGIST

A Gene Expression Signature of Acquired Chemoresistance to Cisplatin and Fluorouracil Combination Chemotherapy in Gastric Cancer Patients

(2011) Hark Kyun Kim et al.   PLoS One

Targeting Epigenetic Regulation of miR-34a for Treatment of Pancreatic Cancer by Inhibition of Pancreatic Cancer Stem Cells

(2011) Dara Nalls et al.   PLoS One

Reduction of Fas/CD95 Promoter Methylation, Upregulation of Fas Protein, and Enhancement of Sensitivity to Apoptosis in Cutaneous T-Cell Lymphoma

(2010) Jianqiang Wu et al.   ARCHIVES OF DERMATOLOGY

Demethylation by 5-aza-2'-deoxycytidine in colorectal cancer cells targets genomic DNA whilst promoter CpG island methylation persists

(2010) David Mossman et al.   BMC CANCER

Epigenetic Regulation of Vitamin D 24-Hydroxylase/CYP24A1 in Human Prostate Cancer

(2010) W. Luo et al.   CANCER RESEARCH

A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations

(2010) Sreenath V. Sharma et al.   CELL

Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer

(2010) Dmitri Lodygin et al.   CELL CYCLE

Phase 1 Study of Valproic Acid in Pediatric Patients with Refractory Solid or CNS Tumors: A Children's Oncology Group Report

(2010) J. M. Su et al.   CLINICAL CANCER RESEARCH

Phase II trial of the histone deacetylase inhibitor belinostat in women with platinum resistant epithelial ovarian cancer and micropapillary (LMP) ovarian tumours

(2010) Helen J. Mackay et al.   EUROPEAN JOURNAL OF CANCER

miR-181b modulates multidrug resistance by targeting BCL2 in human cancer cell lines

(2010) Wei Zhu et al.   INTERNATIONAL JOURNAL OF CANCER

Methylation patterns of genes coding for drug-metabolizing enzymes in tamoxifen-resistant breast cancer tissues

(2010) Sun Jung Kim et al.   JOURNAL OF MOLECULAR MEDICINE-JMM

BCL2L10 protein regulates apoptosis/proliferation through differential pathways in gastric cancer cells

(2010) Jing Da Xu et al.   JOURNAL OF PATHOLOGY

MiR-221 and miR-222 target PUMA to induce cell survival in glioblastoma

(2010) Chun-Zhi Zhang et al.   Molecular Cancer

S110, a 5-Aza-2'-Deoxycytidine-Containing Dinucleotide, Is an Effective DNA Methylation Inhibitor In vivo and Can Reduce Tumor Growth

(2010) J. C. Chuang et al.   MOLECULAR CANCER THERAPEUTICS

Selective inhibition of BET bromodomains

(2010) Panagis Filippakopoulos et al.   NATURE

EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer

(2010) A Singh et al.   ONCOGENE

Possible involvement of stem-like populations with elevated ALDH1 in sarcomas for chemotherapeutic drug resistance

(2010) Honoki   ONCOLOGY REPORTS

Methylation of BNIP3 and DAPK indicates lower response to chemotherapy and poor prognosis in gastric cancer

(2010) Sugita   ONCOLOGY REPORTS

Epigenetic methylation and expression of caspase 8 and survivin in hepatocellular carcinoma

(2010) Seok Cho et al.   PATHOLOGY INTERNATIONAL

In silico analysis and DHPLC screening strategy identifies novel apoptotic gene targets of aberrant promoter hypermethylation in prostate cancer

(2010) Therese M. Murphy et al.   PROSTATE

Impact of the DNA methyltransferases expression on the methylation status of apoptosis-associated genes in glioblastoma multiforme

(2010) E Hervouet et al.   Cell Death & Disease

MicroRNA 133B targets pro-survival molecules MCL-1 and BCL2L2 in lung cancer

(2009) Melissa Crawford et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

miR-221&222 Regulate TRAIL Resistance and Enhance Tumorigenicity through PTEN and TIMP3 Downregulation

(2009) Michela Garofalo et al.   CANCER CELL

Methylation Patterns ofRb1andCasp-8Promoters and Their Impact on Their Expression in Bladder Cancer

(2009) Kianoosh Malekzadeh et al.   CANCER INVESTIGATION

MicroRNA miR-29 Modulates Expression of Immunoinhibitory Molecule B7-H3: Potential Implications for Immune Based Therapy of Human Solid Tumors

(2009) H. Xu et al.   CANCER RESEARCH

Chemoresistant Colorectal Cancer Cells, the Cancer Stem Cell Phenotype, and Increased Sensitivity to Insulin-like Growth Factor-I Receptor Inhibition

(2009) N. A. Dallas et al.   CANCER RESEARCH

PTEN/PI3K/Akt Pathway Regulates the Side Population Phenotype and ABCG2 Activity in Glioma Tumor Stem-like Cells

(2009) Anne-Marie Bleau et al.   Cell Stem Cell

Phase I Study of MG98, an Oligonucleotide Antisense Inhibitor of Human DNA Methyltransferase 1, Given as a 7-Day Infusion in Patients with Advanced Solid Tumors

(2009) R. Plummer et al.   CLINICAL CANCER RESEARCH

Histone H2A.X Tyr142 phosphorylation: A novel sWItCH for apoptosis?

(2009) Manuel Stucki   DNA REPAIR

Epigenetic down-regulation of BIM expression is associated with reduced optimal responses to imatinib treatment in chronic myeloid leukaemia

(2009) Edurne San José-Eneriz et al.   EUROPEAN JOURNAL OF CANCER

The transcription factor ZBP-89 suppresses p16 expression through a histone modification mechanism to affect cell senescence

(2009) Yunpeng Feng et al.   FEBS Journal

Association of reactive oxygen species levels and radioresistance in cancer stem cells

(2009) Maximilian Diehn et al.   NATURE

Chromatin remodeling at Alu repeats by epigenetic treatment activates silenced microRNA-512-5p with downregulation of Mcl-1 in human gastric cancer cells

(2009) Y Saito et al.   ONCOGENE

MicroRNA-221 silencing predisposed human bladder cancer cells to undergo apoptosis induced by TRAIL

(2009) Qiang Lu et al.   UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS

DNA hypomethylation in cancer cells

(2009) Melanie Ehrlich   Epigenomics

Epigenetic control of MHC class II expression in tumor-associated macrophages by decoy receptor 3

(2008) Y.-C. Chang et al.   BLOOD

Restoration of tumor suppressor miR-34 inhibits human p53-mutant gastric cancer tumorspheres

(2008) Qing Ji et al.   BMC CANCER

The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells

(2008) Sendurai A. Mani et al.   CELL

miR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells

(2008) Lin Xia et al.   INTERNATIONAL JOURNAL OF CANCER

Gemcitabine Plus Paclitaxel Versus Paclitaxel Monotherapy in Patients With Metastatic Breast Cancer and Prior Anthracycline Treatment

(2008) Kathy S. Albain et al.   JOURNAL OF CLINICAL ONCOLOGY

An Epstein-Barr virus–encoded microRNA targets PUMA to promote host cell survival

(2008) Elizabeth Yee-Wai Choy et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Intrinsic Resistance of Tumorigenic Breast Cancer Cells to Chemotherapy

(2008) X. Li et al.   JNCI-Journal of the National Cancer Institute

ATM Signaling Facilitates Repair of DNA Double-Strand Breaks Associated with Heterochromatin

(2008) Aaron A. Goodarzi et al.   MOLECULAR CELL

Combination therapy of established cancer using a histone deacetylase inhibitor and a TRAIL receptor agonist

(2008) A. J. Frew et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Aldehyde Dehydrogenase as a Marker for Stem Cells

(2008) Jan Moreb   Current Stem Cell Research & Therapy